The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2017 | Which is the best combination therapy in relapsed and refractory multiple myeloma?
Meletios Dimopoulos, MD, from the Athens School of Medicine, Athens, Greece, discusses combination therapies for relapsed and refractory myeloma treatment at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He describes the most commonly used combinations for patients with aggressive relapse and elderly patients. Prof. Dimopoulos highlights the importance of determining if patients are refractory to particular treatments such as bortezomib or lenalidomide, in which case different regiments could be used.
